TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03610867

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (SAD)
Description: Each subject will receive the sample once by oral administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (MAD)
Description: Each subject will be allocated into one dosing regimen and receive the sample once daily for 5 consecutive days by oral administration.
Study: NCT00836459

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mini Booster
Description: Two telephone-based physical activity consultations, delivered in a motivational interviewing style, at one month and two months from randomisation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Full Booster
Description: Two face-to-face physical activity consultations, delivered in a motivational interviewing style, at one month and two months from randomisation
Study: NCT01256281

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Femoral Nerve Block
Description: Patients enrolled will receive ultrasound guided FNB in addition to standard care. If subjects are experiencing pain in both lower extremities, both extremities will be blocked; if subjects are experiencing pain in one lower extremity, only the affected extremity will be blocked.
Study: NCT00974285

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fuzheng 1
Description: Immunity 1 (Fuzheng 1), 8.75g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, 8.75g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
Study: NCT01573637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raloxifene
Description: The dose of raloxifene hydrochloride administered will be 60 mg/day. Both placebo and the raloxifene will be administered over 6 months. Patients will take one single daily dose administered in the morning. Drug will be given orally in capsule form.
Study: NCT01329406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milnacipran
Description: 1 tablet (100mg) by mouth twice daily for 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet by mouth twice daily for 28 days
Study: NCT03398668

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Relievion device- Treatment stimulation
Description: 1 Hour self-administered treatment specific occipital and supraorbital transcutaneous nerve stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Relievion Device- Sham stimulation
Description: 1 Hour self-administered sham occipital and supraorbital transcutaneous nerve stimulation
Study: NCT01630304

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WelTel SMS service
Description: Weekly text message Mambo? (How are you?) to which participants are required to respond either Shida (problem) or Sawa (OK) within 48 hours. Shida responses and participants who do not respond are called by a clinician.
Study: NCT01603108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: Rifaximin will be initiated post-LT, once the subject is able to tolerate oral medications/diet. Rifaximin will be dosed at 550mg twice daily for 90 days (+/- 10 days) post-LT.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Rifaximin placebo will be initiated post LT, once the subject is able to tolerate oral medications/diet. Rifaximin placebo dosed at 550 mg twice daily for 90 days (+/10 days) post LT.
Study: NCT02751710

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole-body FDG PET-CT alone
Description: FDG PET-CT imaging
Study: NCT01863225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: 20 mg daily, 28-42 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: 40 mg daily, 28-42 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: 40 mg daily, 28-42 days
Study: NCT01573637

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lactosa (placebo arm)
Description: Both placebo and the raloxifene will be administered over 6 months. Patients will take one single daily dose administered in the morning. Drug will be given orally in capsule form.
Study: NCT03515941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130 mg/m2 by IV (Arm 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 625 mg/m2 (Arm 1), 1000 mg/m2 (Arm 1), 750 mg/m2 by PO (Arm 2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 625 mg/m2 (Arm 1), 1000 mg/m2 (Arm 1), 750 mg/m2 by PO (Arm 2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 400 mg/m2 by IV (Arm 1 \& Arm 2)
Study: NCT03540524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG2451 dose regimen A
Description: GLPG2451 oral suspension, daily.
Study: NCT03515941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 400 mg/m2 by IV (Arm 1 \& Arm 2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: 400, 2400 mg/m2 by IV (Arm 1), 400,1200 mg/m2 by IV (Arm 2)
Study: NCT01863225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: 80 mg daily, 28-42 days
Study: NCT01394679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (99m Tc) ECDG (Ethylenedicysteine-Deoxyglucose)
Description: One injection of Technetium-99m Ethylenedicysteine-Deoxyglucose to yield a target dose of 25 mCi (range of 20-30 mCi)by IV push and less than 1 mg of EC-DG

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 18 F FDG followed by PET/CT imaging
Description: Single injection of 18 F FDG range of 10-20 mCi
Study: NCT01375985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVI-7100
Description: Single intravenous administration
Study: NCT03540524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG2451 dose regimen B
Description: GLPG2451 oral suspension, daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG2451 dose regimen B
Description: GLPG2451 oral suspension, daily.
Study: NCT03515941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: 400, 2400 mg/m2 by IV (Arm 1), 400,1200 mg/m2 by IV (Arm 2)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation
Description: 45 Gy in 1.8 Gy/fraction
Study: NCT01375985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single intravenous administration
Study: NCT01638806

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group I: Primary PCI
Description: Patients are treated with Aspirin, ADP-blocker and heparin and field-triaged or transferred immediately to an invasive center for PPCI
Study: NCT03630120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Standard of Care: Lenvatinib 24 mg daily. All participants will start receiving standard of care treatment.~Participants in the Adaptive Therapy regimen will receive TKI therapy in cycles: continuous treatment at the indicated dose until the patients' tumor marker (thyroglobulin in DTC or calcitonin in MTC patients) drops by ≥50% from the level at the time of enrollment (baseline level). A new cycle of TKI treatment will begin when/if the tumor marker increases to or above the baseline level.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenvatinib
Description: Standard of Care: Lenvatinib 24 mg daily. All participants will start receiving standard of care treatment.~Participants in the Adaptive Therapy regimen will receive TKI therapy in cycles: continuous treatment at the indicated dose until the patients' tumor marker (thyroglobulin in DTC or calcitonin in MTC patients) drops by ≥50% from the level at the time of enrollment (baseline level). A new cycle of TKI treatment will begin when/if the tumor marker increases to or above the baseline level.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Standard of Care: Sorafenib 400 mg twice daily. All participants will start receiving standard of care treatment.~Participants in the Adaptive Therapy regimen will receive TKI therapy in cycles: continuous treatment at the indicated dose until the patients' tumor marker (thyroglobulin in DTC or calcitonin in MTC patients) drops by ≥50% from the level at the time of enrollment (baseline level). A new cycle of TKI treatment will begin when/if the tumor marker increases to or above the baseline level.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: Standard of Care: Sorafenib 400 mg twice daily. All participants will start receiving standard of care treatment.~Participants in the Adaptive Therapy regimen will receive TKI therapy in cycles: continuous treatment at the indicated dose until the patients' tumor marker (thyroglobulin in DTC or calcitonin in MTC patients) drops by ≥50% from the level at the time of enrollment (baseline level). A new cycle of TKI treatment will begin when/if the tumor marker increases to or above the baseline level.
Study: NCT02648451

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AYMES ROME
Description: AYMES Rome is a powder, designed to be mixed with 250 ml water to make up a juice style ONS. When made up AYMES Rome provides 300 kcal (1 kcal / ml) and 10.7 g protein. It is not designed to be used as a sole source of nutrition. It is a Food for Special Medical Purposes (FSMP) and must therefore be used under medical supervision.
Study: NCT02606760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P-3073
Study: NCT03540524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG2222
Description: GLPG2222 tablet for oral use, daily.
Study: NCT02606760

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle of P-3073
Study: NCT04143243

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ACT on Life
Description: 1 day group workshop of ACT plus ERS

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Education, Resources, and Support
Description: 1 day group workshop of Education, Resources, and Support
Study: NCT04218162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasmiditan 50mg
Description: Lasmiditan 50mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasmiditan 100mg
Description: Lasmiditan 100mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03480789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: given dexmedetomidine to meet RASS -1 from 22:00 to 6:00 of the next day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: given dexmedetomidine to meet RASS -1 from 22:00 to 6:00 of the next day
Study: NCT03540524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG2222
Description: GLPG2222 tablet for oral use, daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG2222
Description: GLPG2222 tablet for oral use, daily.
Study: NCT03900897

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MED-EL SYNCHRONY PIN Cochlear Implant
Description: Subjects will be implanted with the MED-EL SYNCHRONY PIN Cochlear Implant System with +FLEX24, +FLEX28, +FLEXSOFT electrode arrays. Subjects will be fit with the SONNETEAS (ear-level) and/or RONDO 2 (single-unit) external audio processors.
Study: NCT05237414

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS
Description: 20 minutes of 2.0 mA direct current applied over the right DLPFC

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham tDCS
Description: 15 seconds of 2.0 mA direct current applied over the right DLPFC
Study: NCT03480789

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: eye patch
Description: wearing the eye patch from 22:00 to 6:00 of the next day

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: eye patch
Description: wearing the eye patch from 22:00 to 6:00 of the next day
Study: NCT03630120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Standard of Care: Cabozantinib 140 mg daily. All participants will start receiving standard of care treatment.~Participants in the Adaptive Therapy regimen will receive TKI therapy in cycles: continuous treatment at the indicated dose until the patients' tumor marker (thyroglobulin in DTC or calcitonin in MTC patients) drops by ≥50% from the level at the time of enrollment (baseline level). A new cycle of TKI treatment will begin when/if the tumor marker increases to or above the baseline level.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cabozantinib
Description: Standard of Care: Cabozantinib 140 mg daily. All participants will start receiving standard of care treatment.~Participants in the Adaptive Therapy regimen will receive TKI therapy in cycles: continuous treatment at the indicated dose until the patients' tumor marker (thyroglobulin in DTC or calcitonin in MTC patients) drops by ≥50% from the level at the time of enrollment (baseline level). A new cycle of TKI treatment will begin when/if the tumor marker increases to or above the baseline level.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vandetanib
Description: Standard of Care: Vandetanib 300 mg daily. All participants will start receiving standard of care treatment.~Participants in the Adaptive Therapy regimen will receive TKI therapy in cycles: continuous treatment at the indicated dose until the patients' tumor marker (thyroglobulin in DTC or calcitonin in MTC patients) drops by ≥50% from the level at the time of enrollment (baseline level). A new cycle of TKI treatment will begin when/if the tumor marker increases to or above the baseline level.
Study: NCT01689350

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genotype Detection
Description: To Genotype cases in the experimental group and divide them into three groups, including extensive metaboliser (EM), intermediate metaboliser (IM) and poor metaboliser (PM).
Study: NCT04139681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A. Vogels Sore Throat lozenges
Description: 5 times 1 A. Vogels sore throat lozenges daily for 4 days
Study: NCT01537081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mucinex
Description: Mucinex combines immediate-release (IR) and modified-release guaifenesin in a bilayer tablet. Each tablet was 600 mg of guaifenesin and taken by mouth with a full glass of water.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Immediate-release Guaifenesin
Description: Each tablet was 200 mg of immediate-release (IR) guaifenesin and taken by mouth with a full glass of water.
Study: NCT03630120

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vandetanib
Description: Standard of Care: Vandetanib 300 mg daily. All participants will start receiving standard of care treatment.~Participants in the Adaptive Therapy regimen will receive TKI therapy in cycles: continuous treatment at the indicated dose until the patients' tumor marker (thyroglobulin in DTC or calcitonin in MTC patients) drops by ≥50% from the level at the time of enrollment (baseline level). A new cycle of TKI treatment will begin when/if the tumor marker increases to or above the baseline level.
Study: NCT01460420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bz (Bortezomib)
Description: Bz 1.3 mg/m2 on days +1, +4 and +7. Maintenance therapy and dose reduction pre-specified.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Len (lenalidomide)
Description: Len at a dose of 6 mg po on day -5 and then 4 mg per day in order to maintain serum levels in the range of 6-12 ng /mL.~Maintenance therapy and dose reduction pre-specified.
Study: NCT02689401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxytol

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI 3T scanner
Study: NCT01096121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enalapril
Description: * during 1 month : 0,2 mg/kg/day~* then during 2 months (if no adverse event): 0,35 mg/kg/day~* and then during 6 months (if no adverse event): 0,5 mg/kg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Glucose
Study: NCT01169610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Varenicline is an oral medication with a recommended dosage of 0.5 mg once daily for 3 days, increasing to 0.5 mg twice daily for days 4 to 7, and then to the maintenance dose of 1 mg twice daily for the remaining 23 weeks of treatment. All subjects will receive open-label varenicline in blister packs.
Study: NCT02059057

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LVRC System
Study: NCT00825045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risperidone
Description: Following the baseline clinical and cognitive assessments, risperidone will be initiated at 0.5-1.0 mg/day and subsequently increased by 0.25 - 1.0 mg on a weekly basis with the target of clinical stabilization (i.e. 20 or more % reduction in the total BPRS score) until a maximum dose of 4.0 mg/day is reached. To achieve this, a weekly assessment with BPRS will be performed. Physicians-of-record will be closely liaised with investigators. Dosage modification will be performed following this dosing schedule, however, this can be changed by treating physicians to meet clinical necessity. For example, in case psychotic symptoms are not controlled by this dosing schedule, facilitated dose increment will be allowed.
Study: NCT00768807

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP (continuous positive airway pressure)
Description: Patients treated by CPAP for 06 months

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: CPAP (continuous positive airway pressure)
Description: Patients treated by CPAP for 06 months
Study: NCT03437720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR425899
Description: Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR425899
Description: Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous injection
Study: NCT02068586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Given PO
Study: NCT03540524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG2737
Description: GLPG2737 capsules for oral use, daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG2737
Description: GLPG2737 capsules for oral use, daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG2737
Description: GLPG2737 capsules for oral use, daily.
Study: NCT03735849

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC07-523LS
Description: Administered by intravenous (IV) infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC07-523LS
Description: Administered by intravenous (IV) infusion
Study: NCT01318850

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Therapy
Description: The program has a duration of 40 sessions (one hour of duration), with two sessions for week during four months. It is carried out individually and utilizes paper and pencil tasks. The main technique utilized is the scaffolding (to provide strategies when the patient cannot carry out the task and to withdraw him when he is yet able of doing it alone) in a context of learning without errors.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: The program has a duration of 40 sessions (one hour of duration), with two sessions for week during four months. It is carried out individually and utilizes teaching information and coping skills and neuropsychological issues are not addressed.
Study: NCT01537081

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo tablets in two formulations to match either Mucinex or IR guaifenesin taken by mouth with a full glass of water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets in two formulations to match either Mucinex or IR guaifenesin taken by mouth with a full glass of water
Study: NCT02068586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic Acid
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib Malate
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunitinib Malate + Valproic Acid
Description: Given PO
Study: NCT01818154

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LED phototherapy
Study: NCT01537081

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets in two formulations to match either Mucinex or IR guaifenesin taken by mouth with a full glass of water
Study: NCT01818154

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: LED phototherapy
Study: NCT01229748

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard Care
Description: Clients attend two 90-minute group sessions per week.Treatment lasts for three months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multidimensional Family Therapy
Description: Multidimensional Family Therapy is an outpatient family-based treatment for troubled youth (Liddle, 2002). Treatment duration is 3 months, sessions last 60-90 minutes, with an average of 2 sessions per week and additional extrafamilial work and phone contacts as needed.
Study: NCT01818154

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: narrowband UVB phototherapy

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: narrowband UVB phototherapy
Study: NCT01229748

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Motivational Interviewing Intervention
Description: Youth and parents receive 2 FMII sessions in their homes within 72 hours of the ER incident, and youth will be linked with group treatment lasting 3 months.
Study: NCT03726515

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART-EGFRvIII T cells
Description: autologous T cells that have been engineered to express an extracellular Humanized single chain antibody (scFv) with specificity for EGFRvIII linked to an intracellular signaling molecule comprised of a tandem signaling domain of the 4-1BB and TCRζ signaling modules.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: humanized monoclonal immunoglobulin (Ig) G4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immune checkpoint inhibitory and antineoplastic activities.